Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Angers Cedex 2, France Clinical Trials

A listing of Angers Cedex 2, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to assess the safety, pharmacokinetics and tolerability, describe the dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD [in the absence of establishing the MTD]) for single agent MEDI2228 in adult subjects with multiple myeloma who are either …

Phase

0.73 miles

Learn More »

SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network …

Phase

2.69 miles

Learn More »

A Study to Determine the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ABBV-927 With ABBV-368 Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum …

Phase

3.66 miles

Learn More »

Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma

Glioblastoma treated by Stupp regimen (Temozolomide + radiation therapy) have a different outcome depending on the methylation status of MGMT gene: when the gene is unmethylated, the repair process is active and the prognostic poor. In pre-clinical models, it has been demonstrated that Folic acid could re-methylate the MGMT gene …

Phase

3.66 miles

Learn More »